Abstract B011: Oncogenic neomorphic ATRX-in-frame fusion mutations mechanistically enforce a new immunotherapeutic vulnerability through altered epigenomic regulation
Children with high-risk neuroblastomas (NB) marked by in-frame fusion mutations in the ATRX chromatin remodeler (“ATRX-IFF”) display highly chemoresistant disease. As a result, despite multi-modality therapies, these children have poor overall survival. At present, there are no molecularly-targeted agents for these t...